Four companies request CHMP second opinion
This article was originally published in Scrip
So far in 2014 the European medicines agency's committee for medicinal products for human use (CHMP) has returned four negative opinions for new medicines compared to 16 positive recommendations. However, all four companies who have been unsuccessful with the committee in the New Year have this month called for re-examinations of the decisions.
You may also be interested in...
Helsinn and AB Science plan to conduct additional studies with their products the CHMP turned down this month, in an effort to secure eventual EU approval in the rejected indications. A third company, XBiotech, hasn’t ruled out similar action. New MAAs would be required.
In an exclusive interview, Barbara Lueckel, global head of research technologies at Roche Pharma Partnering, talks about the rationale behind the 2020 deals with Bicycle Therapeutics and Nimble Therapeutics. She gives insight into how deal makers are shifting gears to make deals happen in the challenging environment of the global coronavirus pandemic.
As the COVID-19 pandemic escalates, companies across the world are preparing to roll out commercial test kits for the detection of SARS-CoV-2.